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This study aims to investigate if histo-blood group antigen (HBGA) expressing bacteria
have any protective role on human norovirus (NoV) from acute heat stress. Eleven
bacterial strains were included, belonging to Escherichia coli, Enterobacter cloacae,
Enterobacter aerogenes, Clostridium difficile, Bifidobacterium adolescentis, and B.
longum. HBGA expression of the bacteria as well as binding of human NoV virus-like
particles (VLPs, GI.1, and GII.4 strains) to the bacteria were detected by flow cytometry.
NoV VLPs pre-incubated with HBGA expressing or non-HBGA expressing bacteria were
heated and detected by both direct ELISA and porcine gastric mucin-binding assay.
The NoV-binding abilities of the bacteria correlated well with their HBGA expression
profiles. Two HBGA expressing E. coli (LMG8223 and LFMFP861, both GI.1 and GII.4
binders) and one non-HBGA expressing E. coli (ATCC8739, neither GI.1 nor GII.4 binder)
were selected for the heat treatment test with NoV VLPs. Compared with the same
cell numbers of non-HBGA expressing E. coli, the presence of HBGA-expressing E.
coli could always maintain higher antigen integrity, as well as mucin-binding ability of
NoV VLPs of both GI.1 and GII.4 after heat-treatment at 90◦C for 2 min. These results
indicate that HBGA-expressing bacteria may protect NoVs during the food processing
treatments, thereby facilitating their transmission.
Keywords: norovirus, histo-blood group antigens (HBGAs), bacteria, heat, protection
Introduction
Noroviruses (NoVs), one genera of the Caliciviridae family, were reported as the cause of
between 73% to greater than 95% of global epidemic non-bacterial gastroenteritis outbreaks
and approximately half of all gastroenteritis outbreaks (Atmar and Estes, 2006). NoVs have a
particular set of characteristics compared to other bacterial and viral pathogens that enable them
to spread easily during (food borne) outbreaks and hence contribute to the global presence of
this viral pathogen (Patel et al., 2009). It has been demonstrated that when reaching adulthood
nearly all adults have been exposed to one or more NoVs (Donaldson et al., 2010). Although NoV
infections are generally mild, it may require hospital care and can be associated with mortality
in elderly, chronically ill or immune-compromised patients. Taken into consideration of their
widespreadness, NoVs are causing heavy disease burdens associated with large economic losses
(Van Beek et al., 2013).
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Human NoVs have been very diﬃcult to study since being
discovered in 1972, as the cellular tropism is unknown, they
cannot be grown in culture, and there is no robust small-animal
model. Numerous eﬀorts have been made to search for an in
vitro infection model for human NoVs (Duizer et al., 2004;
Papafragkou et al., 2013) until very recently a breakthrough
has been reported (Jones et al., 2014). Human NoVs have been
observed to bind to histo-blood group antigens (HBGAs) in
a strain-speciﬁc manner both in vitro and in vivo (Tan and
Jiang, 2010; Ruvoën-Clouet et al., 2013). On the other hand,
an individual’s susceptibility to NoVs is correlated with his
HBGA proﬁle in vivo (Tan and Jiang, 2010; Ruvoën-Clouet
et al., 2013). As a number of gram-negative bacteria show blood
group expression (Springer et al., 1961), it has been recently
conﬁrmed that NoVs could bind to an enteric bacterium strain
(SENG-6) closely related to Enterobacter cloacae bearing HBGA-
like molecules located in their extracellular polymeric substances
(EPS; Miura et al., 2013). In the study of Jones et al. (2014) B cells
were identiﬁed as a cellular target of NoVs, and the presence of
HBGA expressing enteric bacteria were required for human NoV
infection of B cells. Based on these facts, we found it of interest to
investigate if the HBGA-expressing bacteria have any protective
role on NoV.
This study aimed at identifying a few HBGA-expressing
bacteria, to conﬁrm the speciﬁc binding of human NoVs to the
HBGA-expressing bacteria, and to investigate the protective eﬀect
of these bacteria on NoVs toward heat treatment. Escherichia
coli, Enterobacter cloacae, Enterobacter aerogenes strains were
included as they are closely related with the reported HBGA-
expressing strains (Springer et al., 1961; Miura et al., 2013).
Among diﬀerent treatments of NoV, the use of high temperature
has been proven to be the most direct and eﬀective strategy, which
is also most widely used in food processing industries for food
safety control and preservation (Rahman, 2007). As reviewed by
Hirneisen et al. (2010), the mechanism of heat inactivation of
viruses is believed to be due to changes in the capsid of the virus
particle. Therefore, this study investigated the protective eﬀect of
bacteria that express HBGA antigens for NoV during heat stress.
Materials and Methods
Bacteria and Virus-Like Particles (VLPs)
Eleven bacterial strains listed in Table 1 were selected from
ATCC, Belgian Coordinated Collection of Microorganisms
(BCCM/LMG), or self-isolated strains of the Laboratory of
Food Microbiology and Food Preservation (LFMFP), Ghent
University. All eleven bacteria were cultured in tryptone soya
broth (TSB, Oxoid, Thermo) at 37◦C. For Clostridium diﬃcile,
Biﬁdobacterium adolescentis, and B. longum, the anaerobic
atmosphere was generated with the use of ANAEROGENTM
COMPACT (Oxoid, Thermo).
A series of anti-HBGAs antibodies was used. Anti-A
antibodies #3, #5, #7, #21 and anti-B antibodies #38, #39, #40, #43,
#49 have been described previously (Le Pendu et al., 1997). The
anti-H type 3/4 Mbr1 was obtained from Enzo Life Sciences; the
anti-H 19-0LE, an anti-H type 2 that shows some cross-reactivity TA
B
L
E
1
|H
is
to
-b
lo
o
d
g
ro
u
p
an
ti
g
en
(H
B
G
A
)e
xp
re
ss
io
n
o
f
th
e
b
ac
te
ri
a
an
d
b
in
d
in
g
o
f
h
u
m
an
n
o
ro
vi
ru
s
(N
o
V
)v
ir
u
s-
lik
e
p
ar
ti
cl
es
(V
L
P
s)
to
th
e
b
ac
te
ri
a.
B
ac
te
ri
a
S
tr
ai
n
B
io
lo
g
ic
al
o
ri
g
in
H
B
G
A
ex
p
re
ss
io
n
V
L
P
b
in
d
in
g
an
ti
-A
21
an
ti
-B
49
an
ti
-H
M
b
r1
an
ti
-H
53
an
ti
-H
19
-0
L
e
an
ti
-L
ea
7-
L
e
an
ti
-L
eb
2-
25
-L
e
an
ti
-L
ex
3E
1
an
ti
-L
ey
12
-4
L
e
G
I.1
G
II.
4
Es
ch
er
ic
hi
a
co
li
LM
G
82
23
C
lin
ic
al
is
ol
at
e
++
+
++
+
++
+
++
+
+
++
+
++
+
E.
co
li
LF
M
FP
86
1
Th
ic
k
w
he
y
pr
od
uc
ts
−
++
+
−
−
−
++
−
−
−
++
++
+
E.
co
li
LF
M
FP
28
9
P
or
k
−
+
−
−
−
−
+
−
−
++
+
E.
co
li
LF
M
FP
85
3
Le
ttu
ce
−
+
−
−
−
+
−
−
−
−
−
E.
co
li
LF
M
FP
13
4
C
ar
ca
ss
−
−
−
−
−
+
−
−
−
−
−
E.
co
li
AT
C
C
87
39
Fe
ce
s
−
−
−
−
−
−
−
−
−
−
−
En
te
ro
ba
ct
er
ae
ro
ge
ne
s
LM
G
20
94
S
pu
tu
m
−
−
−
−
−
+
+
−
+
+
−
En
te
ro
ba
ct
er
cl
oa
ca
e
LM
G
27
83
C
er
eb
ro
sp
in
al
flu
id
−
−
−
−
−
+
+
−
−
−
−
C
lo
st
rid
iu
m
di
ffi
ci
le
LM
G
21
71
7
U
ns
pe
ci
fie
d
−
−
−
−
−
+
−
−
−
+
−
B
ifi
do
ba
ct
er
iu
m
ad
ol
es
ce
nt
is
LF
M
FP
42
2
U
ns
pe
ci
fie
d
−
−
−
−
−
−
−
−
−
−
−
B
.l
on
gu
m
LF
M
FP
42
5
U
ns
pe
ci
fie
d
−
−
−
−
−
−
−
−
−
−
−
Th
e
pe
rc
en
ta
ge
of
po
si
tiv
el
y
st
ai
ne
d
ce
lls
de
te
rm
in
ed
by
flo
w
cy
to
m
et
ry
an
al
ys
is
w
er
e
gr
ou
pe
d
as
in
th
e
fo
llo
w
in
g.
<
1%
:−
;1
%
∼5
%
:+
;5
%
∼1
0%
:
++
;>
10
%
:+
++
.
Frontiers in Microbiology | www.frontiersin.org 2 July 2015 | Volume 6 | Article 659
Li et al. HBGA-expressing bacteria protect NoVs
with Ley, the anti-Lea 7-LE, the anti-Leb 2-25LE, and the anti-
Ley 12-4LE were obtained from Dr. J. Bara (CNRS, Villejuif,
France). The anti-Lex 3E1 was obtained from Dr. D. Blanchard
(EFS, Nantes, France). The speciﬁcities of the monoclonal (mAb)
anti-HBGAs used in the study were described in Table 2.
Virus-Like Particles of human NoV GI.1 (Norwalk virus) and
GII.4 (Dijon 1996) were generated using a previously described
method (Caddy et al., 2014). Recombinant baculoviruses
containing the VP1 protein from NoV GI.1 and GII.4 were
generated, and VLPs were produced by infection of Hi5 insect
cells. VLPs were released from the infected Hi5 cells by
three rounds of freeze-thawing and then clariﬁed by removal
of cellular debris (6,000 × g for 30 min) and baculovirus
(14,000 × g for 30 min). The VLPs were partially puriﬁed
through a 30% (wt/vol) sucrose cushion in TNC buﬀer
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM CaCl2)
containing the protease inhibitor leupeptin at 150,000 × g
for 2 h. The pelleted VLPs were resuspended in TNC
and further puriﬁed by isopynic centrifugation in cesium
chloride (150,000 × g; 18 h). The resultant VLP bands were
collected by puncture, and the solution containing VLPs was
dialyzed against PBS prior to quantiﬁcation by bicinchoninic
acid (BCA) protein assay (Thermo Scientiﬁc) and storage
at −80◦C.
Flow Cytometry Analysis
For the HBGA expression test, 6 h cultures of E. coli, Enterobacter
cloacae, and Enterobacter aerogenes (plateau growth phase), and
48 h culture of Clostridium diﬃcile, B. adolescentis, and B. longum
(plateau growth phase) were collected. The concentrations of
bacteria culture were normalized with TSB to an OD570 of
0.4 (around 108 CFU/ml). In the following the bacterial pellet
(100 μl per sample) were washed twice with phosphate buﬀered
saline (PBS, pH 7.4) before being re-suspended in PBS-0.1%
bovine serum albumin (BSA, 100 μl per sample) and incubated
TABLE 2 | Specificities of the monoclonal (mAb) anti-HBGAs used in the
study.
mAb dentification Specificity Dilution
Anti-A #3 A types 3/4 1:10
#5 A type 2 1:10
#7 A type 5, ALey > ALeb 1:10
#21 A types 1−5, ALeb 1:50
Anti-B #38 B type 2, BLey 1:10
#39 B type 2 1:10
#40 B type 2 1:10
#43 B type 2 1:10
#49 B types 1−5, BLey 1:10
Anti-H/Lewis Mbr1 H types 3/4 1:60
19-OLE H type 2 > Ley 1:300
#53 H type 2 1:10
12-4LE Ley 1:300
2-25LE Leb > Lea 1:100
7-LE Lea 1:100
3E1 Lex 1:10
at 37◦C for 1 h to block the non-speciﬁc binding. After
centrifugation at 6,000 × g for 5 min, mouse monoclonal
antibodies (Table 2) diluted in PBS-0.1% BSA were added to
the bacteria pellets, mixed by vortex for a few seconds and
incubated at 37◦C for 1 h. HBGAs were detected using a series
of mouse monoclonal anti-A, anti-B, anti-H and anti-Lewis
antibodies that present diﬀerent speciﬁcities HBGA subtypes. An
irrelevant IgG3 (Sigma) was included as the negative control.
After two washings by centrifugation at 6,000 × g for 5 min in
PBS, the last incubation was performed with Alexa Fluor R© 488
Goat anti-mouse Fab fragment (Beckman Coulter) at dilution
of 1:200 in PBS-0.1% BSA at 37◦C for 1 h. After ﬁnal washes
(centrifugation at 6,000 × g for 5 min in PBS), ﬂuorescence
analysis was performed on a BDTM LSR II ﬂow cytometer (5,000
events were set-up as the gating, Becton Dickinson, Rungis,
France).
The binding of human NoV VLPs to the bacteria was
identiﬁed using the above protocol with a few variations.
Human NoV VLP of GI.1 and GII.4 were diluted in PBS-
0.1% BSA to 5 and 10 μg/ml, respectively, added to the
washed and blocked bacteria pellet at 100 μl per sample,
mixed and incubated at 37◦C for 1 h. After washing, anti-
VLP rabbit polyclonal antibodies (lp130 for GI.1 and lp132
for GII.4, self-produced antibody by INSERM) diluted in
PBS-0.1% BSA at 1:200 were added, incubated and washed,
followed by incubation with DylightTM 488 Goat Anti-Rabbit
IgG (H + L) antibody (KPL, Gaithersburg, MD, USA) at
a dilution of 1:200 in PBS-0.1% BSA. After ﬁnal washes,
ﬂuorescence analysis was performed on the BDTM LSR II ﬂow
cytometer (5,000 events were set-up as the gating, Becton
Dickinson).
In order to control for the speciﬁcity of the anti-HBGA
antibodies and of VLPs binding to bacteria, E. coli strains
LMG8223 was treated by α-N-acetylgalactosaminidase (New
England Biolabs) at 37◦C for 1 h. Chinese hamster ovary
(CHO) cells, transfected with rat α1,2- fucosyltransferase B
cDNA and the rat A enzyme cDNA as described previously
(Marionneau et al., 2002), were utilized as a positive control
for this enzymatic treatment. E. coli LFMFP861 was treated
by the α-galactosidase from coﬀee beans (Sigma) at 37◦C for
1 h. The A and B antigens expression on treated and untreated
cells were detected by the use of antibody #21 and #49,
respectively. Additionally, E. coli LFMFP861 was treated by the
α-galactosidase (Sigma) and an α1,2-fucosidase from B. biﬁdum,
respectively, at 37◦C for 1 h. The binding of human NoV VLPs
GI.1 to the untreated and treated bacteria were then quantiﬁed as
above.
Fluorescence Microscopy
Escherichia coli LMG8223 was stained with the use of antibody
#21 and an irrelevant IgG3, respectively, as described for
the ﬂow cytometry experiments. In the ﬁnal incubation step,
besides Alexa Fluor R© 488 Goat Anti-Mouse IgG (H + L)
antibody (Life Technologies), the blue-ﬂuorescent Hoescht
nucleic acid stain (NucBlue Live stain, Life Technologies)
was also included. The stained cells were ﬁxed with 4%
paraformaldehyde and mounted on slides with Vectashield R©
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(Vector laboratories, Burlingame, CA, USA). The sealed slides
were observed under a Zeiss Axiovert 200 ﬂuorescence
microscope.
Heat Treatment
Escherichia coli LMG8223, LFMFP861, and ATCC8739 (100 μl
per sample) were normalized to an OD570 of 0.4 and washed with
PBS. Human NoV VLPs diluted in PBS (GI.1 at 2.5 μg/ml and
GII.4 at 5 μg/ml) were added to the bacterial pellet (100 μl per
sample) and mixed well by vortexing. The mixtures (100 μl per
sample in 0.5 ml thin-walled PCR tubes) were heated at 90◦C for
2min in a PCR cycler (MJ Research PTC200 Thermal Cycler) and
placed on ice to cool down before further tests.
ELISA-based Microtiter Plate Assays
For the direct ELISA, the mixtures of NoV VLPs and bacteria
were diluted in carbonate buﬀer (CBS, 50 mM sodium carbonate,
pH 9.6 at 1:10, directly coated on Nunc Maxisorp immunoplates
and incubated overnight at 4◦C. The plates were washed three
times with 0.05% Tween 20 in PBS (PBS-T) and then blocked
with 5% skim milk (BD DifcoTM) in PBS for 1 h at 37◦C. Anti-
VLP rabbit polyclonal antibodies (lp130 for GI.1 and lp132 for
GII.4) diluted in PBS-5% skimmilk (BDDifcoTM) at 1:1,000 were
added, and another 1-h incubation at 37◦C took place. After three
times washing with PBS-T, the ﬁnal 1-h incubation at 37◦C was
with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG
(Uptima) at a 1:4,000 dilution in 5% skim milk (BD DifcoTM) in
PBS. After three times washing with PBS-T, the enzyme signals
were detected using TMB (3,3′,5,5′-tetramethylbenzidine) as the
substrate (BD Bioscience, San Jose, CA, USA), and the reaction
was stopped with 1 N phosphoric acid. The optical density was
read at 450 nm (OD450). The non-coated wells were included as
blank controls.
Porcine gastric mucin, which contains mixed type A, H type
1, and Lewis b HBGAs was reported to be a good candidate
for binding of many human NoVs strains (Tian et al., 2008).
For the porcine gastric mucin-binding assay, Nunc Maxisorp
immunoplates were pre-coated with porcine gastric mucin
(Sigma M1778, 2 μg/well) in CBS overnight at 4◦C. The plates
were washed three times with PBS-T. The wells were then blocked
with 5% skim milk (BD DifcoTM) in PBS for 1 h at 37◦C before
the mixtures of NoV VLPs and bacteria (untreated and treated)
were added to each well and incubated for 1 h at 37◦C. After three
times washing with PBS-T, the following procedures (incubation
with antibodies and HRP activity measurement) were performed
as for the direct ELISAdescribed above, except the enzyme signals
were detected with TMB One Solution (Promega). The mucin-
coated wells without the addition of VLPs were included as blank
controls.
Data Analysis
Statistical analyses were performed by one-way analysis of
variance (the Tukey’s test was used as a post hoc test) with
SPSS 22 for Windows (SPSS, Inc., Chicago, IL, USA). Signiﬁcant
diﬀerences were considered when P was<0.05.
Results
HBGA-Expression and Human NoV
VLP-Binding to the Bacteria
Table 1 shows the results of an initial screening of the HBGA
expression and NoV VLPs binding ability of the eleven
bacterial strains detected by ﬂow cytometry analysis. The
NoV-binding abilities of the bacteria correlated well with
their HBGA expression proﬁles. Both human NoV VLPs
GI.1 and GII.4 bound to E. coli LMG8223, which had high
expression of type A antigen (42.5%) and lower expressions
of type B, H, and Lewis antigens (1∼10%) and E. coli
LFMFP861, which had high expression of type B antigen
(14.3%) and lower expression of Lewis a antigen (6.2%). Bacterial
strains with weak HBGA expressions (E. coli LFMFP289,
LFMFP853, LFMFP134, Enterobacter aerogenes LMG2094,
Enterobacter cloacae LMG2783, and Clostridium diﬃcile
LMG21717) showed weak or no NoV binding ability. Bacteria
without HBGA expression (E. coli ATCC8739, B. adolescentis
LFMFP422, B. longum LFMFP425) showed no NoV binding
ability.
Followed by the initial screening as shown in Table 1, the
HBGA expression and NoV VLPs binding for E. coli LMG8223
and E. coli LFMFP861 were further analyzed.
Firstly, the type A antigen expression on E. coli LMG8223,
the type B antigen expression on E. coli LFMFP861 and the
binding of NoV VLPs GI.1 and GII.4 to E. coli LMG8223 and
E. coli LFMFP861 were repeated independently three times by
ﬂow cytometry analysis (Table 3). The qualitative positive results
were conﬁrmed repeatedly while the percentage of positively
stained cells varied largely probably due to the variation of HBGA
expression on bacteria cells from diﬀerent batches (although the
bacteria were always inoculated at the same cell numbers and
cultured for the same time).
Secondly, the ﬂuorescence microscopy results, which showed
E. coli LMG8223 stained by anti-A antibody #21, were supplied
as a visual control of the ﬂow cytometry analysis (Figure 1).
Thirdly, in order to get some insight into the HBGA structures
present on bacteria, we used several diﬀerent anti-A, B, and
H antibodies that react with more or less restricted sets of A,
B, and H epitopes. Indeed these can be mono or difucosylated
and vary according to the type of precursor structure (types 1–
5; Marionneau et al., 2001). We observed that those antibodies
TABLE 3 | The HBGA expression and binding of human NoV VLPs to the
bacteria E. coli LMG8223 and E. coli LFMFP861 (percentage of positively
stained cells determined by flow cytometry analysis, three independent
tests).
Average (%) SD (±%)
E. coli LMG8223 Type A antigen expression 28.5 13.4
VLP GI.1 binding 5.6 1.5
VLP GII.4 binding 10.9 8.3
E. coli LFMFP861 Type B antigen expression 6.8 6.6
VLP GI.1 binding 9.8 4.3
VLP GII.4 binding 14.2 18.7
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FIGURE 1 | Examples of flow cytometry and fluorescence microscopy
results. (A) Flow cytometry plot of Escherichia coli LMG8223 stained by an
irrelevant IgG3 (negative control); (B) Flow cytometry plot of E. coli LMG8223
stained by anti-A antibody #21; (C) Fluorescence microscopy picture of E. coli
LMG8223 stained with an irrelevant IgG3 (negative control); (D) Fluorescence
microscopy picture of E. coli LMG8223 stained by anti-A antibody #21.
reactive with either E. coli LMG8223 or E. coli LFMFP861 were
those that have the broadest reactivity to A or B epitopes.
Thus, E. coli LMG8223 showed positive reactions with anti-A
antibodies #21 (42.5%) and #7 (68%), which have very strong,
and broad A reactivity, but not with antibodies #3, or #5
(<1%), which have more restricted anti-A speciﬁcity (Le Pendu
et al., 1997). Similarly, E. coli LFMFP861 showed strong positive
reaction with anti-B antibody #49 (14.3%), which has a broad
reactivity with a group of B-like molecules, but showed low
or no reaction with antibodies #38 (3.9%), #39 (2.7%), #40
(<1%), and #43 (3.9%), known to be more restricted anti-B
(Le Pendu et al., 1997). These results indicate that not all anti-
HBGA recognize bacteria, even though they bind to human red
cells.
Furthermore, in order to conﬁrm speciﬁcity of the
anti-A or B staining of the bacteria, we attempted to
remove these epitopes using speciﬁc glycosidases. An
α-N-acetylgalactosaminidase that speciﬁcally catalyzes the
hydrolysis of α-linked N-acetylgalactosamine residues from
the blood group A epitope and an α-galactosidase that
removes the terminal galactose residue of the blood group
B epitope were used. Treatment of CHO cells expressing
the A antigen by the α-N-acetylgalactosaminidase clearly
decreased the A antigen expression from 66.8% positive cells
as detected by ﬂow cytometry to 28.6%, showing eﬃcacy of
the enzyme treatment. It had a more limited eﬀect on the A
antigen expression of E. coli LMG8223 (From 74.8 to 64.9%),
suggesting that the bacteria blood group A structures might
be slightly diﬀerent from mammalian structures which serve
as substrates for this glycosidase. This could also explain why
NoV GI.1 showed less binding to E. coli LMG8223 than GII.4
(Table 1), which has more ﬂexible binding sites based on
the observation from crystallographic studies (Prasad et al.,
2014).
Treatment of E. coli LFMFP861 with α-galactosidase
decreased the B antigen expression (from 14.3 to 3.6%)
unambiguously demonstrating speciﬁcity of the anti-B staining.
NoV GI.1 binding to that E. coli strain was quite surprising
since it does not recognize either B or Lewis a blood group
antigens (Huang et al., 2005) which were the only ones that we
could evidence on E. coli LFMFP861 (Table 1). It was therefore
hypothesized that there might be an unknown H-type structure
present on E. coli LFMFP861, which does not react with the
anti-H antibodies used in this study, but could bind to NoV GI.1.
Consistent with this hypothesis, the binding of NoV GI.1 VLP to
E. coli LFMFP861 was decreased following pre-treatment of the
bacteria with an α1,2-fucosidase that removes the α1,2-linked
fucose which constitutes the essential building block of H
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antigens (from 9.2 to 6.6%). Furthermore, NoV GI.1 binding
to E. coli LFMFP861 was increased after a pre-treatment of
the bacteria with the α-galactosidase, which likely exposed
more H antigen on the bacteria (from 9.2 to 13.1%), further
conﬁrming speciﬁcity of the VLPs binding. The exact structure
of the bacterial HBGAs remains to be determined. Nevertheless,
an authentic B blood group tetrasaccharide from E. coli 086
has been previously characterized (Yi et al., 2005). Likewise,
an α1,2-fucosyltransferase was isolated from E. coli 0127:K63
(Pettit et al., 2010). This enzyme speciﬁcally synthesized H
type 3 only, which may not be an optimal substrate for the
α1,2-fucosidase that we used and which is not recognized
by most anti-H antibodies. The low eﬀect of either the α-N-
acetylgalactosaminidase or the α1,2-fucosidase on anti-A or GI.1
VLPs binding, respectively, might thus be due to diﬀerences
in the precise blood group epitope and to the context of their
presentation on the bacterial surface as compared to that of the
cognate mammalian epitopes.
Protection of NoV VLPs from Heat Treatment
by HBGA Expressing Bacteria
In order to determine if the HBGA-dependent attachment
of NoVs to bacteria could play some role in the virus
transmission, we tested if it could protect virions from acute
heat stress as encountered during cooking. To this aim,
E. coli LMG8223, E. coli LFMFP861 (both GI.1 and GII.4
binders), and E. coli ATCC8739 (neither GI.1 nor GII.4
binder) were used for the heat treatment test with NoV VLPs.
Direct ELISA and mucin-binding ELISA were performed in
order to measure the antigenicity and receptor-binding ability
of NoV VLPs, respectively. Three independent tests were
performed and the results (OD450) are shown in Figure 2.
Blank controls as the background were with OD450 values
around 0.1.
In the absence of bacteria or in the presence of non-HBGA
expressing E. coli ATCC8739, detection of NoV GI.1 VLPs by a
speciﬁc polyclonal antiserum was decreased to background level
after 90◦C treatment for 2min. By contrast, the immunoreactivity
of the VLPs remained after the heat treatment upon incubation
with HBGA expressing bacteria E. coli LMG8223 and LFMFP861,
of which VLPs with E. coli LMG8223 showed signiﬁcantly
(p < 0.05) higher immunoreactivity after the heat treatment
than NoV GI.1 VLPs without bacteria or with E. coli ATCC8739
or LFMFP861 (Figure 2A). Likewise although not signiﬁcantly,
higher porcine mucin binding levels of NoV GI.1 VLPs were
obtained after heat treatment upon incubation with HBGA
FIGURE 2 | Protection of histo-blood group antigen (HBGA) expressing
bacteria on human norovirus (NoV) virus-like particles (VLPs) toward
heat treatment. (A,B) Antigenicity detection of NoV GI.1 and GII.4 in the
absence of bacteria, in the presence of non-HBGA expressing E. coli
ATCC8739 or HBGA-expressing E. coli LMG8223 and LFMFP861 before (white
bars) or after (black bars) heat treatment at 90◦C for 2 min. (C,D) Mucin-binding
ELISA results of NoV GI.1 and GII.4 in the absence of bacteria, in the presence
of non-HBGA expressing E. coli ATCC8739 or HBGA expressing E. coli
LMG8223 and LFMFP861 before (white bars) or after (black bars) heat
treatment at 90◦C for 2 min. ∗Significant differences as explained in the Section
“Results.” Each data point is an average of three independent tests, and each
error bar represents the data range.
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expressing bacteria E. coli LMG8223 and LFMFP861 than NoV
GI.1 VLPs without bacteria or with non-HBGA expressing E. coli
ATCC8739 (Figure 2C).
When the same experiments were performed using NoV
GII.4 VLPs, the direct ELISA results showed that GII.4 were
more resistant to heat treatment than GI.1, which is contrary
to previous assumptions that GI are more resistant than GII
to environmental conditions and removal during the sewage
treatment process (da Silva et al., 2007). Indeed, detection of
GII.4 VLPs without bacteria and with non-HBGA expressing
E. coliATCC8739 by direct ELISA decreased after heat treatment,
albeit not to background level, whilst in the presence of HBGA-
expressing E. coli LMG8223 and E. coli LFMFP861, detection
of GII.4 epitopes increased after heat treatment and showed
signiﬁcantly (p < 0.05) higher immunoreactivity than NoV
GII.4 VLPs without bacteria or with non-HBGA expressing
E. coli ATCC8739 (Figure 2B). It is likely that in the latter
condition, the immunodetection of GII.4 VLPs was higher
following heat treatment than in the non-heated control due
to partial degradation of the VLPs that resulted in unmasking
of epitopes. After heat treatment, the mucin-binding ability of
GII.4 VLPs was also quite well preserved by incubation with
HBGA-expressing bacteria, whilst it was entirely lost in the
absence of bacteria or in the presence of HBGA non-expressing
E. coli ATCC8739. NoV GII.4 VLPs with E. coli LFMFP861
showed signiﬁcantly (p < 0.05) higher mucin-binding level than
NoV GII.4 VLPs without bacteria or with E. coli ATCC8739 or
LMG8223 (Figure 2D). These results indicated that the presence
of HBGA-expressing bacteria could help maintain integrity of
GII.4 VLPs upon heat treatment.
Discussion
The major observation of this study is that compared with
the same cell numbers of non-HBGA expressing E. coli, the
presence of HBGA-expressing E. coli could maintain higher
antigen integrity as well as mucin-binding ability for both NoV
VLPs GI.1 and GII.4 after heat-treatment at 90◦C for 2 min.
In general, studies on the HBGA expression of bacteria are
not abundant in literature, therefore in this study eﬀorts were
made ﬁrstly on the HBGA identiﬁcation and conﬁrmation on
the selected bacterial strains before studying on the eﬀect of the
HBGA structures on viruses.
It is shown in this study that there can be large variations
of HBGA expression between diﬀerent bacterial strains (even
closely related genetically). Moreover, the HBGA expression
levels of one particular bacterial strain can vary to large extents
(as shown in Table 3) from diﬀerent cultural batches (although
the bacteria were always inoculated at the same cell numbers
and cultured for the same time). This is not very surprising
as the HBGA-like substances can be secondary metabolites of
bacteria and the expression can be regulated by some unknown
factors, which still need to be studied in the future. Therefore
the HBGA expression of E. coli LMG8223 and E. coli LFMFP861
were conﬁrmed qualitatively, and the data are considered to
be quantitatively comparable only for samples from the same
batches (5000 cells were analyzed by ﬂow cytometry for each
sample).
Compared with previous studies (Springer et al., 1961; Miura
et al., 2013), the use of multiple speciﬁc monoclonal ABH and
Lewis antibodies in this study supplied more information on
the variable HBGA-structures of diﬀerent bacteria. In addition,
the reactions of E. coli LMG8223 and E. coli LFMFP861 with
several diﬀerent anti-A, B, and H antibodies that react with
more or less restricted sets of A, B, and H epitopes, and results
from treating A or B epitopes on these two bacteria using
speciﬁc glycosidases indicated that the HBGA epitopes present
on bacteria may not be identical with those present on human
red cells (A type 2, B type 2, or H type 2). It was previously
reported that oysters, which are important vectors for human
NoVs, may play a selective role in the transmission of diﬀerent
NoV strains via speciﬁc binding to carbohydrate ligands (Le
Guyader et al., 2013). According to this study, the binding
ability of diﬀerent NoV strains to HBGA-expressing bacteria
can be variable, indicating that the HBGA-expressing bacteria,
which can spread widely in the nature (Springer et al., 1961),
may contribute to the NoV strain selective transmission as
well.
The reactions of human NoVs toward heat treatments have
been studied by many researchers. As reviewed by Bertrand et al.
(2012), these studies were conducted under diﬀerent conditions
with variable models and methods. Our results in this study is
consistent with the report of Hirneisen and Kniel (2013) showing
that heating of a NoV GII strain at 80 and 100◦C for 5 min could
decrease the binding of the virus to porcine gastric mucin to levels
under the cut-oﬀ.
It has to be noted that the results obtained on NoV
VLPs from direct ELISA and mucin-binding ELISA may not
mirror authentic NoV infectivity. Nevertheless, these results
do suggest that HBGA-expressing bacteria may protect NoVs
during the food processing treatments and possibly in the
human gastrointestinal tract before causing infection. Through
this protection eﬀect, HBGA-expressing bacteria may facilitate
the virus transmission. In the future, more treatment conditions
should be tested and the protective mechanisms of the HBGA-
expressing bacteria on NoVs should be investigated, especially
if a routine method can be established to measure infectivity of
human NoVs.
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